03rd week of 2022 patent applcation highlights part 24 |
Patent application number | Title | Published |
20220017584 | GROWTH DIFFERENTIATION FACTOR 15 FUSION PROTEINS - GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules. | 2022-01-20 |
20220017585 | CXCR3 LIGAND - The present disclosure relates to CXCR3 ligands having resistance to DPPIV and having CXCR3-expressing cell migration-inducing activity, and specifically to N-terminal amino acid modifications and N-terminal amino acid sequences that are important for resistance to DPPIV and CXCR3-expressing cell migration-inducing activity. | 2022-01-20 |
20220017586 | EXPOSED COLLAGEN-TARGETED FUSION CYTOKINE FOR IMMUNE MODULATION IN INVASIVE CANCERS AND LESIONS OF INFECTIONS - Provided herein are new compositions and methods to target pharmaceutical agents to pathological areas by utilizing fusion polypeptides. These fusion polypeptides contain two or more domains: (i) aptamer sequences that bind to exposed collagenous (XC-) proteins present in pathological areas, including cancerous and viral lesions, (ii) immunomodulators, such as cytokines, and optionally (iii) at least one linker joining the two domains or at the terminus of the polypeptide. In some cases, the linker is a rigid linker, e.g., a rigid helical linker. Also provided herein are methods of treating cancer and/or infectious diseases using the new fusion polypeptides. | 2022-01-20 |
20220017587 | DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10 - The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders. | 2022-01-20 |
20220017588 | SPLIT INTERLEUKIN MIMETICS AND THEIR USE - Conditionally active receptor agonists that, when activated, bind to IL-2 receptor β | 2022-01-20 |
20220017589 | FUSION PROTEINS OF GLP-1 AND GDF15 AND CONJUGATES THEREOF - The present disclosure provides fusion polypeptides comprising GLP-1 and GDF15, the polypeptide complexes, and the conjugates thereof. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided. | 2022-01-20 |
20220017590 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE - The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation. | 2022-01-20 |
20220017591 | Heterodimeric Relaxin Fusions and Uses Thereof - The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure. | 2022-01-20 |
20220017592 | HIGH-AFFINITY TCR FOR AFP RECOGNITION - Provided in the present invention is a T-cell receptor (TCR) having the characteristic of binding a FMNKFIYEI-HLA A0201 complex; and the binding affinity of the TCR to the FMNKFIYEI-HLA A0201 complex is at least 5 times that of a wild-type TCR to the FMNKFIYEI-HLA A0201 complex. Further provided in the present invention is a fusion molecule of the TCR with a therapeutic agent. The TCR can be used alone or in combination with the therapeutic agent, so as to target a tumor cell presenting the FMNKFIYEI-HLA A0201 complex. | 2022-01-20 |
20220017593 | COMPOSITIONS AND METHODS FOR USE OF RECOMBINANT T CELL RECEPTORS FOR DIRECT RECOGNITION OF TUMOR ANTIGEN - Provided are compositions and methods for prophylaxis and/or therapy of a variety of cancers which express a NY-ESO-1 antigen. Included are recombinant T cell receptors (TCRs), polynucleotides encoding them, expression vectors that include the polynucleotides, and cells into which the polynucleotides have been introduced to produce modified cells, including CD4 | 2022-01-20 |
20220017594 | IL-2 DEPENDENT NK-92 CELLS WITH STABLE FC RECEPTOR EXPRESSION - Provided herein are populations of IL2 Dependent haNK® cells, which express a high affinity CD16 but does not express IL-2. These cells maintain stable expression of Fc receptor CD16 while retaining cytotoxicity. In some embodiments, the expression level of CD16 decreases no more than 20% when the cells are activated as compared to expression level of CD16 on the cells before activation. Compositions and kits comprising the cells, and methods of making and using the IL2 Dependent haNK® cells are also provided. | 2022-01-20 |
20220017595 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2022-01-20 |
20220017596 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide, an epitope-presenting peptide, and class I MHC polypeptides. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual. | 2022-01-20 |
20220017597 | MULTIMERIC T-CELL MODULATORY POLYPEPTIDES AND METHODS OF USE THEREOF - The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory N polypeptide, a MUC1 epitope-presenting peptide, and class I MHC polypeptides. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual. The present disclosure provides a T-cell modulatory multimeric polypeptide (TMMP) comprising: a) a first polypeptide; and b) a second polypeptide, wherein the TMMP comprises a MUC1 peptide; a first major histocompatibility complex (MHC) polypeptide; a second MHC polypeptide; one or more immunomodulatory polypeptides; and optionally an immunoglobulin (Ig) Fc polypeptide or a non-lg scaffold. | 2022-01-20 |
20220017598 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. | 2022-01-20 |
20220017599 | Composition and Method for Regulating Migration of Immune Cells - A composition and method for regulating the migration of immune cells. The method for regulating the migration of immune cells comprises the step of strengthening or weakening the interaction between Hsp90 and α4 integrin in immune cells. Also provided is an immune cell capable of strengthening or weakening the interaction between Hsp90 and α4 integrin and a pharmaceutical composition thereof. The present method and pharmaceutical composition may be used to treat pathogen infections and autoimmune diseases or to kill tumor cells. | 2022-01-20 |
20220017600 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND PERICYTE COMPOSITION - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction. | 2022-01-20 |
20220017601 | TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF - Disclosed in the present disclosure are a TGF-β receptor fusion protein pharmaceutical composition and a use thereof. Specifically, the pharmaceutical composition comprises a TGF-β receptor fusion protein in a sodium citrate buffer, and the TGF-β receptor fusion protein comprises a PD-L1 antibody targeting portion and a TGF-βRII extracellular region. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant. | 2022-01-20 |
20220017602 | OCULAR COMPOSITIONS AND METHODS - A biotherapeutic ophthalmic solution that may include a silk-derived protein as an active ingredient. The specific formulation of an ophthalmic composition is critical to meeting user requirements, to the delivery of dosage forms, and to maintaining product stability. The formulations described herein are ophthalmic solutions that are comfortable to the user while product stability is maintained, even after long-term storage. Numerous excipients, manufacturing processes, and container closures were evaluated for their ability to stabilize silk-derived protein under ambient and accelerated conditions. Analyses showed that only a very small subset of vehicle formulations were able to meet the high physiochemical property standards required for stabilizing protein-containing therapeutic ophthalmic solution formulations. | 2022-01-20 |
20220017603 | METHOD FOR ISOLATION OF SOLUBLE POLYPEPTIDES - Polypeptides with biophysical properties such as solubility, stability, high expression, monomericity, binding specificity or non-aggregation, including monomeric human heavy and light chain variable domains (V | 2022-01-20 |
20220017604 | ANTI-SARS-CoV-2 MONOCLONAL ANTIBODIES - The present invention relates to antibodies or antigen-binding fragments that are useful for treating coronavirus infections (e.g., COVID-19 caused by SARS-CoV-2). The present invention also relates to various pharmaceutical compositions and methods of treating coronavirus using the antibodies or antigen-binding fragments. | 2022-01-20 |
20220017605 | HUMAN ANTIBODIES TARGETING ZIKA VIRUS NS1, NS1 POLYPEPTIDES AND USES THEREOF - In one aspect, provided herein are antibodies that bind to Zika virus non-structural protein 1 (NS1) and compositions comprising the same. In a specific embodiment, such antibodies or compositions thereof may be used to passively immunize a subject against Zika virus. In another embodiment, such antibodies or compositions thereof may be used to diagnose a Zika virus infection. In another aspect, provided herein are recombinant NS 1 polypeptides and compositions comprising the same that may be used to immunize a subject against Zika virus disease. | 2022-01-20 |
20220017606 | SARS-COV-2(SARS2, COVID-19) ANTIBODIES - The invention relates to antibodies and antigen-binding fragments thereof that recognize SARS-Cov-2 spike proteins (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. in some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection, In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2). | 2022-01-20 |
20220017607 | MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF - The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders. | 2022-01-20 |
20220017608 | Methods of Treating Inflammatory Pain - The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of inflammatory pain and/or symptoms of inflammatory pain, and to a method of treating and/or preventing inflammatory pain and/or symptoms of inflammatory pain using an anti-CGRP antibody. | 2022-01-20 |
20220017609 | CELL-PENETRATING ANTI-DNA ANTIBODIES AND USES THEREOF INHIBIT DNA REPAIR - Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies. | 2022-01-20 |
20220017610 | Antibodies Blocking DLL4-Mediated Notch Signalling - The present invention is directed to antibodies that interact with DLL4 and inhibit it from binding to NOTCH receptors. The invention also includes nucleic acids encoding the antibodies and methods of using the antibodies in research and in the prevention or treatment of various diseases and conditions. | 2022-01-20 |
20220017611 | NEW ANTI TAU SVQIVYKPV EPITOPE SINGLE DOMAIN ANTIBODY - The invention relates to generation, optimization and characterisation of VHH targeted against Tau MTBD (microtubule-binding domain) with high affinity, obtained by screening from a naïve synthetic library. The inventors optimized version of a lead VHH which is able to inhibit Tau aggregation in vitro and in HEK 293 aggregation-reporting cellular model, providing a new tool in Tau immunotherapies. Accordingly the invention relates to new VHH antibody that specifically binds with high affinity Tau species, especially the epitope region involved in Tau aggregation. Moreover, the inventors found that immunization with the optimized version of this lead VHH prevented the formation of neurofibrillary tangles induced by injection of extracellular h-AD in mouse model. Thus, these specific antibodies can be used for the therapy of tauopathy disorders such as Progressive supranuclear palsy (PSP). | 2022-01-20 |
20220017612 | ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF - Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGFβ1 on cells but not to LAP-TGFβ1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications. | 2022-01-20 |
20220017613 | STEM CELL FACTOR INHIBITOR - Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases. | 2022-01-20 |
20220017614 | Anti-IL6 Agent for Treating Coronavirus Infection - An anti-IL6 agent that blocks binding of IL-6 to IL-6 receptor, for example, an anti-IL6 antibody comprising a heavy chain variable region of SEQ ID NO:99 and a light chain variable region of SEQ ID NO:97, is useful in the treatment or prevention of infection of a human with SARS-CoV-1 and/or SARS-CoV-2. | 2022-01-20 |
20220017615 | CD47 ANTIBODY, PREPARATION METHOD THEREFOR AND USES THEREOF - An antibody targeting CD47, a preparation method therefor and uses thereof. A novel mouse or human-mouse chimeric antibody targeting CD47. A method for preparing the monoclonal antibody. The monoclonal antibody of the present invention can bind CD47 antigen with high specificity, has high affinity and significant activities, such as anti-tumor activity. | 2022-01-20 |
20220017616 | TIGIT AND CD112R BLOCKADE - Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof. | 2022-01-20 |
20220017617 | EFFICIENTLY EXPRESSED EGFR AND PD-L1 BISPECIFIC BINDING PROTEINS - Bispecific Fabs-In-Tandem Immunoglobulin (FTT-Ig) binding proteins that bind both EGFR and PD-L1 simultaneously are disclosed. Such bispecific EGFR/PD-L1 FIT-Ig binding proteins are efficiently expressed and are useful for blocking EGFR signaling, for blocking PD-L1 signaling, and for treating cancer. | 2022-01-20 |
20220017618 | USE OF TIM-3 ANTIBODY IN PREPARATION OF MEDICINES FOR TREATING TUMORS - Disclosed is use of a TIM-3 antibody in preparation of medicines for treating tumors. Specifically, provided is use of the TIM-3 antibody or an antigen-binding fragment thereof in preparation of medicines for treating non-small cell lung cancer, the TIM-3 antibody containing a heavy chain variable region shown in SEQ ID NO: 33 and a light chain variable region shown in SEQ ID NO: 36. Further, also provided is use of the TIM-3 antibody or the antigen-binding fragment thereof and a PD-1 antibody or an antigen-binding fragment thereof in joint preparation of medicines for treating tumors. | 2022-01-20 |
20220017619 | TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY - This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity. | 2022-01-20 |
20220017620 | ANTI-B7-H3 ANTIBODY, PREPARATION METHOD THEREFOR, CONJUGATE AND APPLICATION THEREOF - An anti-B7-H3 antibody, a preparation method therefor, a conjugate and an application thereof. The anti-B7-H3 antibody comprises a complementarity determining region: one or more of heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3. A sequence of the complementarity determining region is as described in the specification. The anti-B7-H3 antibody is a fully human antibody, has a unique antigen binding epitope, and can specifically bind B7-H3 antigen on tumor cells. Moreover, the antibody can rapidly internalize into cells after binding to tumor cells, and can be used for ADC drug development to obtain better anti-tumor activity and efficacy to achieve the purpose of treating cancers. | 2022-01-20 |
20220017621 | Combination Therapy for Cancer - This invention relates generally to a combination therapy for the treatment of cancer, particularly to a combination of (i) a bifunctional molecule comprising a TGFβRII or fragment thereof capable of binding TGFβ and an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1) and (ii) at least one additional anti-cancer therapeutic agent. | 2022-01-20 |
20220017622 | THERAPEUTIC ANTIBODIES AND THEIR USES - The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof. | 2022-01-20 |
20220017623 | TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A WNT SIGNALING INHIBITOR - The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a CEA CD3 bispecific antibody and a Wnt signaling inhibitor. | 2022-01-20 |
20220017624 | ANTI-ALPHA-4-BETA-7 ANTIBODIES - The present disclosure provides anti-α4β7 antibodies that bind human α4β7, their methods of making, and their uses to treat patients with HIV infection. | 2022-01-20 |
20220017625 | TUMOR-SPECIFIC ANTI-EGFR ANTIBODY AND APPLICATION THEREOF - The present invention provides a tumor-specific anti-EGFR antibody and application thereof. The antibody can be used for preparing targeted antitumor drugs and tumor diagnosis drugs. | 2022-01-20 |
20220017626 | EGFR BINDING PROTEINS AND METHODS OF USE - Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders. | 2022-01-20 |
20220017627 | ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF - Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides. | 2022-01-20 |
20220017628 | BISPECIFIC POLYPEPTIDES FOR ENGAGEMENT OF CAR EXPRESSING IMMUNE CELLS WITH ANTIGEN PRESENTING CELLS AND USES THEREOF - The present application is directed to bispecific polypeptides comprising a first domain binding an antigen on an antigen presenting cell (ARC) and a second domain binding an antigen on an immune cell expressing a chimeric antigen receptor (CAR). Nucleic acids, vectors and host cells used in producing the polypeptide of the invention are also disclosed. Compositions comprising the bispecific polypeptides and methods of treating cancer and stimulating activation and expansion of immune cells in vivo and in vitro are also disclosed. | 2022-01-20 |
20220017629 | OX40 ANTIBODY, PREPARATION METHOD THEREOF AND USE THEREOF - Provided are a murine or human-mouse chimeric antibody targeting OX40 and a preparation method therefor, wherein the antibody binds to the OX40 antigen and has an anti-tumor activity and other activities. | 2022-01-20 |
20220017630 | ANTI-TNFR2 ANTIBODY AND USE THEREOF - An antibody or an antigen-binding fragment thereof capable of specifically binding to TNFR2, the antibody or the antigen-binding fragment thereof is capable of regulating the function of immune cells and may be used as a medicament to treat diseases related to immune-related disorders, such as tumors. | 2022-01-20 |
20220017631 | BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 AND AN IMMUNOLOGICAL DRUG FOR COMBINED USE IN TREATING MULTIPLE MYELOMA - The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma. | 2022-01-20 |
20220017632 | ANTI-OX40 MONOCLONAL ANTIBODY AND APPLICATION THEREOF - Provided in the present invention are an anti-OX40 monoclonal antibody or an antigen-binding fragment thereof, and a corresponding isolated polynucleotide, expression vector, recombinant cell, pharmaceutical composition, and application thereof. The present antibody can be used for the treatment of cancer or autoimmune disease. | 2022-01-20 |
20220017633 | HUMANIZED BCMA ANTIBODY AND BCMA-CAR-T CELLS - The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising V | 2022-01-20 |
20220017634 | ENGINEERED BISPECIFIC PROTEINS - In one aspect, bispecific proteins having the ability to specifically bind to two antigens, and having an Fc polypeptide that comprises a modified CH3 domain and specifically binds to a transferrin receptor, are provided. | 2022-01-20 |
20220017635 | BISPECIFIC ANTIBODY BINDING TO TfR - The present invention relates to a bispecific antibody in which an N-terminal side polypeptide is bound to an IgG portion that binds to TfR, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof. | 2022-01-20 |
20220017636 | MAGEB2 BINDING CONSTRUCTS - The present invention relates to antibody constructs comprising a domain which binds to a MAGEB2 peptide complexed with an HLA and optionally, another domain which binds to CD3. Moreover, the invention provides polynucleotides encoding the antibody constructs, vectors comprising said polynucleotides and host cells transformed or transfected with said polynucleotides or vectors. Furthermore, the invention provides processes for producing the antibody constructs of the invention, medical uses of said antibody constructs, and kits comprising said antibody constructs. | 2022-01-20 |
20220017637 | AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2 - The present invention relates to Her2-targeted bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same. | 2022-01-20 |
20220017638 | METHOD OF TREATING ATHEROSCLEROSIS - The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII. | 2022-01-20 |
20220017639 | METHODS FOR INCREASING THERMOGENIC ADIPOCYTES - In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes. | 2022-01-20 |
20220017640 | ACTIVATABLE BISPECIFIC ANTIBODIES - The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies. | 2022-01-20 |
20220017641 | BISPECIFIC ANTIBODIES AND USES THEREOF - This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities. | 2022-01-20 |
20220017642 | Bispecific binding molecules binding to VEGF and Ang2 - Bispecifc binding molecules binding to both VEGF and Ang2, preferably in the form of immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with VEGF- and/or Ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described. | 2022-01-20 |
20220017643 | HETERODIMER MOLECULE BASED ON CH3 DOMAIN, AND PREPARATION METHOD AND USE THEREOF - The disclosure is directed to a heterodimer molecule, comprising a first polypeptide chain and a second polypeptide chain, and the first polypeptide chain comprises a first CH3 domain of an antibody heavy chain constant region, the second polypeptide chain comprises a second CH3 domain of an antibody heavy chain constant region. Comparing to a corresponding wild-type CH3 domain of a human antibody heavy chain constant region, the first CH3 domain and the second CH3 domain comprise amino acid mutations at specific positions, for example T366+K409+K392 and T366+L368+Y407+D399+F405, respectively. | 2022-01-20 |
20220017644 | Method of Manufacturing a Biodegradable Healthcare Product - A method is provided of manufacturing a biodegradable healthcare product for environmental purposes such as reducing waste. The main ingredients include a quantity of potato starch, a quantity of corn starch, and a quantity of avocado seeds. The quantity of potato starch, the quantity of corn starch, and the quantity of avocado seeds are all pulverized. The quantity of potato starch, the quantity of corn starch, and the quantity of avocado seeds are amalgamated into a quantity of biodegradable powder. A molding process is executed by manufacturing a sterile healthcare product from the quantity of biodegradable powder. The sterile healthcare product can be any type of healthcare product such as, but not limited to, a pharmaceutical product bottle, a nutraceutical product bottle, a one test kit container, a band-aid container, a dental floss container, a swab container, a syringe, an inhaler, a dropper, or a tampon. | 2022-01-20 |
20220017645 | CHARGE-BEARING CYCLODEXTRIN POLYMERIC MATERIALS AND METHODS OF MAKING AND USING SAME - The present disclosure relates to charge-bearing polymeric materials and methods of their use for purifying fluid samples from micropollutants, such as anionic micropollutants. | 2022-01-20 |
20220017646 | METHODS AND COMPOSITIONS FOR ACHIEVING HEMOSTASIS AND STABLE BLOOD CLOT FORMATION - Provided is a tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject. | 2022-01-20 |
20220017647 | CHITOSAN-DERIVED COMPOSITIONS - The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders. | 2022-01-20 |
20220017648 | Method, Kit, and Device for Preparing Glycan from Glycoprotein - Provided are a method for preparing a glycan from a glycoprotein, and a kit and a device for preparing a glycan from a glycoprotein. The method includes (I) a step of obtaining a glycan-containing sample by bringing a glycan releasing solution that contains a hydroxylamine compound and a basic reagent into contact with the glycoprotein and releasing the glycan from the glycoprotein; (II) a step of adsorbing a glycan having a length of a monosaccharide or more on a purifying agent for purifying the glycan by bringing the glycan-containing sample into contact with the purifying agent, which is composed of a compound having a betaine structure; and (III) a step of eluting the glycan from the purifying agent. | 2022-01-20 |
20220017649 | SPHINGAN OLIGOSACCHARIDES - Disclosed herein is a sphingan oligosaccharide composition, its uses, and a process for preparing the same. | 2022-01-20 |
20220017650 | NOVEL PROCESS FOR THE PURIFICATION OF SUGAMMADEX SODIUM - The present invention relates to an improved process for the preparation of Sugammadex sodium (1). It further relates to a novel process for the purification of Sugammadex sodium (1) having impurity A less than 2% (w/w) and impurity E less than 0.1% (w/w) | 2022-01-20 |
20220017651 | PROCESS FOR PRODUCING CHLORINATED BUTYL RUBBER - The invention relates to an energy efficient, fast and environmentally favourable process for the preparation of chlorinated butyl rubbers, that uses hypochlorous acid (HOCl) and/or dichlorine monoxide (Cl | 2022-01-20 |
20220017652 | PROCESS FOR MODIFYING THE SURFACE POLARITY OF RUBBER SUBSTRATES - The present invention relates to a process for modifying the surface polarity of elastomeric rubber substrates to facilitate their cold bonding to other rubber substrates or non-elastomeric substrates of a different material, preferably metal, by chlorinating the elastomeric rubber substrate surface by treatment with a chloride-containing composition and a peroxymonosulfate-containing composition. Further aspects relate to the thus-obtained surface-modified rubber substrates, processes of bonding them to other substrates by use of an adhesive, as well as the thus-obtained bonded substrates. | 2022-01-20 |
20220017653 | SOLUTION POLYMERIZATION PROCESS - Disclosed herein is a system for solution polymerization comprising a reactor system that is operative to receive an anti-solvent, a monomer, and a solvent, and to react the monomer to form a polymer; where the anti-solvent is not a solvent for the polymer and is operative to reduce the lower critical solution temperature; a plurality of devolatilization vessels located downstream of the reactor system, where each devolatilization vessel operates at a lower pressure than the preceding devolatilization vessel and wherein the plurality of devolatilization vessels receives a polymer solution from the reactor system; and a liquid-liquid separator that is operative to receive a polymer solution from the reactor system and to facilitate a separation between the polymer and volatiles by reducing the pressure and temperature of the polymer solution in the liquid-liquid separator. | 2022-01-20 |
20220017654 | PROCESS FOR PREPARING RANDOM COPOLYMERS - The invention relates to a process for preparing random copolymers comprising monomers derived from conjugated diener and C | 2022-01-20 |
20220017655 | PROCESS FOR THE PRODUCTION OF ISOOLEFIN POLYMERS USING A TERTIARY ETHER - The invention relates to an efficient process for the preparation of isoolefin polymers such as polyisobutene or butyl rubber by polymerization of isobutene and optionally further monomers in the presence of an initiator system comprising at least one boron or aluminium compound and at least one tertiary alkyl ether. | 2022-01-20 |
20220017656 | METHOD FOR PREPARING A POLYMER DISPERSION - The present disclosure relates to a process and/or method for producing a polymer dispersion by free-radically initiated emulsion polymerization of radically polymerizable ethylenically unsaturated monomers within a polymerization reactor. The polymer dispersion obtained is transferred to a post-treatment reactor and is post-treated therein. The polymer dispersion within the post-treatment reactor is conveyed, simultaneously to the post-treatment, to a circuit for filtration and analysis and is then subsequently fed back into the post-treatment reactor. | 2022-01-20 |
20220017657 | Hybrid Supported Catalyst and Method of Preparing Polyolefin Using the Same - Provided are a hybrid supported catalyst which includes two or more kinds of transition metal compounds having the following Chemical Formulas 1 and 2, thereby preparing a polyolefin, particularly, a high-density polyethylene having a molecular structure which is optimized to improve tensile strength of a chlorinated polyolefin compound, and a method of preparing a polyolefin using the same: | 2022-01-20 |
20220017658 | HALOGEN RECOVERY IN A WET PROCESS FOR HALOGENATING UNSATURATED ISOOLEFIN COPOLYMER - A process for producing a halogenated isoolefin copolymer involves contacting an unsaturated isoolefin copolymer cement, the cement containing an unsaturated isoolefin copolymer dissolved in an organic solvent, under halogenation conditions with a halogenating agent and an aqueous solution of an organic peracid oxidant to form a two-phase reaction medium having an organic phase and an aqueous phase, the organic peracid oxidant capable of converting hydrogen halide to free halogen. The process leads to higher halogen utilization even when the cement contains significant amounts of water and without the use of an emulsifier. | 2022-01-20 |
20220017659 | HALOGEN RECOVERY IN A PROCESS FOR HALOGENATING UNSATURATED ISOOLEFIN COPOLYMER - A process for producing a halogenated isoolefin copolymer involves contacting an unsaturated isoolefin copolymer cement, the cement containing an unsaturated isoolefin copolymer dissolved in an organic solvent, under halogenation conditions with a halogenating agent and an aqueous solution of an organic peracid oxidant to form a two-phase reaction medium having an organic phase and an aqueous phase, the organic peracid oxidant capable of converting hydrogen halide to free halogen. The process leads to higher halogen utilization even when the cement contains significant amounts of water and without the use of an emulsifier. | 2022-01-20 |
20220017660 | Oligomerization Catalyst System Activation And Related Ethylene Oligomerization Processes And Reaction Systems - Disclosed herein are oligomerization processes in which ethylene and a catalyst system are first combined for a suitable residence time in an activation vessel, prior to introduction into a reaction zone to oligomerize ethylene to form a desired oligomer product, such as 1-hexene and/or 1-octene. Related oligomerization reaction systems that include the activation vessel also are disclosed. In these oligomerization processes and reaction systems, the catalyst system can be fully activated as it leaves the activation vessel and enters the reaction zone, thus providing greater catalyst utilization and less catalyst waste. | 2022-01-20 |
20220017661 | RAPID ACTIVATION PROCESS AND ACTIVATION TREATMENTS FOR CHROMIUM CATALYSTS FOR PRODUCING HIGH MELT INDEX POLYETHYLENES - Processes for activating chromium polymerization catalysts, which can use lower maximum activation temperatures and shorter activation times than conventional activation methods, and provide polyethylenes with high melt indices, broader molecular weight distributions, and lower long chain branching content. The activation process can comprise heating a supported chromium catalyst in an inert atmosphere to a first temperature (T | 2022-01-20 |
20220017662 | METHOD FOR PRODUCING POROUS MICROSTRUCTURE - The invention relates to production of a porous microstructure using the high internal phase emulsion (HIPE) templating technology. The invented method involves subjecting an emulsion prepared by emulsification of two immiscible phases to forced sedimentation, such as subjecting the emulsion to centrifugation, so as to increase the volume ratio of the dispersed phase to the continuous phase to obtain a high internal phase emulsion (HIPE), following by curing the continuous phase, whereby the porous microstructure thus produced has an increased porosity. | 2022-01-20 |
20220017663 | Polyethylene and Its Chlorinated Polyethylene - There are provided a polyethylene capable of improving tensile strength while maintaining excellent processability and Mooney viscosity characteristics when preparing a chlorinated polyethylene compound by implementing a molecular structure having a low content of low molecular weight and a high content of high molecular weight, and a chlorinated polyethylene prepared using the same. | 2022-01-20 |
20220017664 | METHOD FOR PRODUCING SOLID CATALYST COMPONENT FOR POLYMERIZATION OF OLEFIN, SOLID CATALYST COMPONENT FOR POLYMERIZATION OF OLEFIN, CATALYST FOR POLYMERIZATION OF OLEFIN, METHOD FOR PRODUCING CATALYST FOR POLYMERIZATION OF OLEFIN AND METHOD FOR PRODUCING POLYMER OFOLEFIN - A solid catalyst component for polymerization of an olefin having a polymerization activity equivalent to or higher than a solid catalyst component having a phthalic acid ester compound or diether compound as an internal electron-donating compound, and can produce an olefin polymer having excellent bulk density and low content of olefin oligomers. A solid catalyst component for polymerization of an olefin is obtained by: (i) bringing compounds selected from particular phthalic acid ester compounds (A), a magnesium compound and a halogen-containing titanium compound into contact; (ii) bringing the first contact product obtained in step (i) and compounds selected from particular diether compounds (B) into contact, and washing the second contact product; and (iii) obtaining a contact product between the washed second contact product and a halogen-containing titanium compound, washing the contact product, and bringing it into contact with particular phthalic acid ester compounds (A) and a halogen-containing titanium compound. | 2022-01-20 |
20220017665 | Polyethylene and Method for Preparing the Same - In the present disclosure, there are provided a polyethylene having improved low-temperature sealing properties with an increase in the content and molecular weight of a low crystalline polymer, and a method for preparing the same. | 2022-01-20 |
20220017666 | Ethylene-Based Polymer Composition with Branching and Process for Producing the Same - The present disclosure provides a polymer composition. In an embodiment, an ethylene-based polymer composition is provided and is formed by high pressure (greater than or equal to 100 MPa), free-radical polymerization, by reacting: ethylene monomer and a mixture of hydrocarbon-based molecules, with each hydrocarbon-based molecule comprising three or more terminal alkene groups. | 2022-01-20 |
20220017667 | Ethylene/1-Hexene Copolymer Having Excellent Long-Term Physical Properties and Processability - Provided is an ethylene/1-hexene copolymer which has excellent long-term physical properties and processability, and thus may be usefully applied to manufacturing high-pressure resistant heating pipes, PE-RT pipes, large-diameter pipes, or the like. | 2022-01-20 |
20220017668 | Metallocene Catalyst Systems With Chemically-Treated Solid Oxides For Producing Ethylene-Based Plastomers And Elastomers - Polymerization processes for producing ethylene-based plastomers and elastomers having densities less than 0.91 g/cm | 2022-01-20 |
20220017669 | FLUOROPOLYMER COMPOSITION FOR COMPONENTS OF LIGHT EMITTING APPARATUSES - The invention pertains to a fluoropolymer composition comprising certain tetrafluoroethylene/perfluoromethyvinylether copolymers having well-defined TFE/MVE monomer composition and possessing low molecular weight and a white pigment, to the use of this latter for manufacturing shaped articles, and to shaped articles therefrom, including components of light emitting apparatuses, e.g. LED assemblies. | 2022-01-20 |
20220017670 | PLASTIC WASTE-DERIVED POLYMERS AND RESINS AND METHODS OF MAKING THE SAME - The present disclosure relates to a composition that includes | 2022-01-20 |
20220017671 | MODIFIED POLYOLEFIN RESIN - A modified polyolefin resin may be capable of obtaining an intended adhesion strength regardless of a kind of a base resin thereof even when graft modification is carried out by using an α,β-unsaturated carboxylic acid derivative having a cyclic structure. Such a modified polyolefin resin may be a modified product of a polyolefin resin and satisfying (A) and (B): (A): a modifying component includes an α,β-unsaturated carboxylic acid derivative having a cyclic structure; and (B): a ring-opening degree expressed by formula (1) is 40 or more. | 2022-01-20 |
20220017672 | POLYMER, SEPARATING AGENT, PRODUCTION METHOD OF POLYMER, SEPARATION METHOD OF COMPOUND, AND PRODUCTION METHOD OF COMPOUND - The present invention relates to a polymer including at least one structure selected from the group consisting of a structure represented by General Formula (3) described below and a structure represented by General Formula (4) described below: | 2022-01-20 |
20220017673 | Dielectric Film Forming Compositions - This disclosure relates to a dielectric film forming composition that includes a plurality of (meth)acrylate containing compounds, at least one fully imidized polyimide polymer, and at least one solvent. | 2022-01-20 |
20220017674 | CURABLE HEAT-SEAL ADHESIVES FOR BONDING POLYMERS - Curable compositions include a urethane (meth)acrylate oligomer having a number—average molecular weight of at least 6000 g/mol; at least one mono(meth)acrylate monomer; a multifunctional crosslinking monomer chosen from acrylate monomers, methacrylate monomers, or combinations thereof; and an ethylene-vinyl acetate grafted terpolymer. The mono(meth)acrylate monomers may include a first mono(meth)acrylate with Tg between 50° C. and 175° C. and a second mono(meth)acrylate with Tg between −50° C. and 30° C. The curable compositions may be applied onto a surface of a substrate then cured to form a low-tack adhesive layer on the surface. The curable compositions may be cured by exposure to visible radiation, UV radiation, LED radiation, laser radiation, electron-beam radiation, peroxide, accelerator, or heat. Methods for bonding substrates include contacting a second substrate to a tow-tack adhesive layer on a first substrate, then heating the low-tack adhesive layer to bond the substrates and form a laminate. | 2022-01-20 |
20220017675 | Photostable Compositions Comprising Para-Alkoxyl Phenyl Substituted Propenoic Acid (APP) Copolymer Derivatives - The present disclosure relates, according to some embodiments, to photostable photoactive compositions comprising (a) at least one photoactive compound that develops within itself an excited state energy when subjected to UV radiation and (b) a block copolymer comprising a plurality of blocks, wherein the block copolymer is operable to quench the excited state energy. | 2022-01-20 |
20220017676 | TIRE COMPRISING A POLYMERIC COMPOSITION COMPRISING A THERMOPLASTIC ELASTOMER COMPRISING UNITS DERIVED FROM DIPHENYLENE ETHER MONOMER - A tire comprises a polymeric composition comprising at least one block thermoplastic elastomer comprising at least one elastomer block and at least one thermoplastic block, in which each elastomer block comprises at least 70% by weight of units resulting from isoprene, with respect to the weight of said elastomer block, and at least one thermoplastic block comprises 40% to 80% by weight of units resulting from one or more styrenic monomers and 10% to 63% by weight of units resulting from diphenylethylene, with respect to the weight of said thermoplastic block. | 2022-01-20 |
20220017677 | Solventless Adhesive Composition and Process for Making and Use in Forming a Laminate - The present disclosure provides a process comprising providing an isocyanate component A comprising a blend of (i) an aromatic isocyanate prepolymer and (ii) an aliphatic isocyanate prepolymer; providing a polyol component B comprising a blend of; (i) a phosphate-functional polyol, (ii) a polyether polyol, and (iii) an element selected from the group consisting of a polyurethane polyol, a polyester polyol and a combination thereof; mixing component A and component B to form a solventless adhesive (SLA) composition, wherein a weight ratio of component A to component B is from 2:1 to 1:1, the SLA composition having a pot life from 30 min to 60 min at 40 C; applying the SLA composition between a first film and a second film to form a raw laminate; and curing the raw laminate to form a laminate product. | 2022-01-20 |
20220017678 | POLYURETHANE COMPOSITION RAW MATERIAL LIQUID AGENT, POLYURETHANE COMPOSITION, AND MIXING SYSTEM - A polyurethane composition raw material liquid agent comprises a polyol or an isocyanate, and a filler. The polyurethane composition raw material liquid agent has a viscosity at 25° C. and a rotation speed of 60 rpm of 950 mPa·s or less, and is filled in at least one cartridge-like container of a caulking gun that includes two cartridge-like containers and is capable of mixing two components. | 2022-01-20 |
20220017679 | PRODUCTION OF RIGID POLYURETHANE FOAM - What are described are (a) a composition suitable for production of rigid polyurethane foam, comprising at least one isocyanate component, a polyol component, optionally a catalyst that catalyses the formation of a urethane or isocyanurate bond, optionally blowing agents, where the composition additionally comprises polyalkylsiloxane (PAS) containing no polyether modification, and polyether-modified siloxane, (b) a process for producing rigid polyurethane foam using polyalkylsiloxanes and polyether-modified siloxane, (c) the rigid polyurethane foam Thus obtainable and (d) the use thereof. | 2022-01-20 |
20220017680 | NITROGEN-FREE AND LOW-NITROGEN CROSSLINKING ADDITIVES FOR COLD-CURE FLEXIBLE SLABSTOCK FOAM HAVING IMPROVED COMPRESSION AND AGING PROPERTIES - Process for producing cold-cure flexible slabstock PU foams by reaction of at least one polyol component and at least one isocyanate component in the presence of water and at least one catalyst and at least one crosslinker, wherein no nitrogen-containing crosslinkers having an expanded OH number above 1000 mg KOH/g are employed in a total amount >0.5 parts by weight, preferably >0.1 parts by weight, based on 100 parts by weight of polyol. | 2022-01-20 |
20220017681 | POLYURETHANE FOAM FORMULATION AND SOUND INSULATION WITH FOAMS BASED THEREON (MOTOR CAPSULE) - Disclosed is a polyurethane foam formulation based on conventional polyether and novolac polyols with, in particular, MDI for the production of soft-elastic PUR moulded foams with viscoelastic properties, in particular for sound insulation with foams based thereon. | 2022-01-20 |
20220017682 | MACROMONOMERIC STABILIZER, PREPARATION METHOD THEREOF, AND METHOD FOR PREPARING POLYMERIC POLYOL - A macromonomeric stabilizer, a preparation method thereof, a method for preparing a polymeric polyol using same, and the polymeric polyol prepared. Also disclosed are a soft polyurethane foam obtained by foaming a composition of the polymeric polyol prepared and a polyisocyanate, and a molded product comprising the soft polyurethane foam. The preparation method of the macromonomeric stabilizer comprises the following steps: reacting a polyol with a tricarboxylate not comprising a polymerizable ethylenically unsaturated double bond, or a derivative thereof, to form an adduct; and reacting the resulting adduct with an epoxide comprising a polymerizable ethylenically unsaturated double bond. The macromonomeric stabilizer of the present invention has a low viscosity, comprises a plurality of active sites, and can be directly used in subsequent reactions. The preparation method of the macromonomeric stabilizer can be carried out under normal pressure, without the need for end-blocking with ethylene oxide. | 2022-01-20 |
20220017683 | MOISTURE-CURABLE SILYLATED POLYMER RESIN COMPOSITION WITH REDUCED MOISTURE SENSITIVITY - There is provided herein a silylated polyurethane composition, a process of preparing a silylated polyurethane polymer, and an adhesive, sealant or coating containing a silylated polyurethane made therewith. | 2022-01-20 |